The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has granted 'in principle' approval to Bharat Biotech for conduct of 'Phase III superiority study and Phase III booster dose study' trials for its intranasal COVID-19 vaccine, reported news agency ANI.
Earlier in mid-December, the company sought permission to conduct clinical trials for its intranasal booster dose.
Bharat Biotech aims to conduct clinical trials on 5,000 subjects (50 per cent vaccinated with Covishield and 50 per cent vaccinated with Covaxin).
Bharat Biotech also manufactures the COVID-19 vaccine Covaxin, which was recently given emergency use authorisation for 12-18 year olds.
Veteran Socialist Leader Dr Baba Adhav Passes Away At 95 In Pune
Uttar Pradesh Govt Promotes 4 IAS Officers To Principal Secretary Rank; 20 From 2010 Batch Cleared For Secretary Post
Navi Mumbai News: Swedish Man Dies After Falling From 4th Floor Of Residential Building In Sanpada; ADR Registered, Probe Underway
UP CM Yogi Adityanath Calls For Door-To-Door Verification To Remove Fake & Ineligible Voters
(With inputs from Agencies)
.jpg)
